Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
203 Clinical Trials near Camarillo, CA
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerAdjustable Low-profile Stentriever for Ischemic Stroke
Thousand Oaks, California
This trial is testing a new device that removes blood clots from brain vessels in stroke patients with severe symptoms. The goal is to see if it works better than current methods.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Acute Brain Hemorrhage, Renal Failure, Severe Hypertension, Others
Must Not Be Taking:Oral Anticoagulants, Heparin, DOACs
168 Participants Needed
TAVR for Aortic Stenosis
Thousand Oaks, California
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:65+
Key Eligibility Criteria
Disqualifiers:Age < 65, LVEF ≤ 20%, Others
650 Participants Needed
Neovasc Reducer for Refractory Angina
Thousand Oaks, California
This trial tests the Reducer system, a device to improve heart blood flow, in patients with severe chest pain not relieved by standard treatments and unsuitable for surgery. The device works by redirecting blood flow to needy heart areas by narrowing a vein. The Reducer system has been shown to improve chest pain symptoms and heart function in patients with persistent chest pain.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Recent ACS, Uncontrolled Hypertension, Severe COPD, Others
Must Be Taking:Anti-anginal Agents
380 Participants Needed
CardioMech MVRS for Mitral Valve Regurgitation
Thousand Oaks, California
This trial is testing a new device called the CardioMech Mitral Valve Repair System (MVRS) to help patients with a leaky heart valve who are at high risk for surgery. The device aims to fix the valve and improve heart function without needing open-heart surgery. The HARPOON Beating Heart Mitral Valve Repair System (MVRS) has shown it can safely and effectively repair the heart valve while the heart is still beating.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Rheumatic Heart Disease, Prior Endocarditis, Others
25 Participants Needed
reSept ASD Occluder for Atrial Septal Defect
Thousand Oaks, California
This trial is testing the safety and effectiveness of the reSept ASD Occluder, a device that closes a specific type of heart hole. It targets patients with secundum atrial septal defect and works by sealing the hole like a patch.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:< 84
Key Eligibility Criteria
Disqualifiers:Pregnancy, Valve Dysfunction, Cardiovascular Abnormalities, Others
Must Be Taking:Aspirin, Heparin
250 Participants Needed
WATCHMAN FLX Device for Atrial Fibrillation
Los Angeles, California
The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Active Bleed, Recent Stroke, Others
Must Be Taking:Non-vitamin K Anticoagulants
3000 Participants Needed
Mitral Valve Repair vs. MitraClip Implantation for Mitral Valve Regurgitation
Thousand Oaks, California
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Secondary MR, Tricuspid Regurgitation, EF <30%, Others
500 Participants Needed
Millipede System for Mitral Regurgitation
Thousand Oaks, California
To evaluate the feasibility and safety of the Millipede Transcatheter Annuloplasty Ring System in subjects with functional mitral regurgitation
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Heart Transplant, Stroke, Severe Aortic Stenosis, Renal Insufficiency, Severe Liver Disease, Others
Must Not Be Taking:Anticoagulation Therapy
4 Participants Needed
Transcatheter Mitral Valve Replacement for Mitral Valve Regurgitation
Los Angeles, California
Study to evaluate the feasibility, safety and performance of the HighLife trans-septal Transcatheter Mitral Valve in patients with moderate-severe and severe mitral regurgitation who are at high risk for surgical treatment.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Mitral Stenosis, Rheumatic Valve Disease, Others
Must Be Taking:GDMT
30 Participants Needed
AltaValve for Mitral Valve Regurgitation
Thousand Oaks, California
Prospective, single-arm, multicenter study to evaluate the safety and performance of the AltaValve for the treatment of moderate to severe or severe mitral valve regurgitation in subjects who are considered high risk for mortality and morbidity from conventional open-heart surgery.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Pregnancy, Cognitive Issues, Low LVEF, Others
Must Not Be Taking:Aspirin, Heparin, Warfarin
15 Participants Needed
Tricuspid Valve Repair for Tricuspid Regurgitation
Thousand Oaks, California
This trial is testing a device called TriClip that helps fix a leaky heart valve without major surgery. It is for patients with severe valve issues who are at high risk from traditional surgery. The device clips the valve flaps together to reduce leakage and improve heart function. This procedure is less invasive and more cost-effective than medication treatment.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Pulmonary Hypertension, Hypertension, Valve Procedure, Others
Must Be Taking:Diuretics
572 Participants Needed
Transcatheter Valve Repair for Mitral Regurgitation
Thousand Oaks, California
This trial tests a new device called Edwards PASCAL that fixes leaky heart valves without surgery. It is for patients who can't have surgery or haven't improved with other treatments. The device helps the valve close better, stopping blood from leaking backward.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Stroke, Severe COPD, Pregnancy, Others
Must Be Taking:Heart Failure Medications
1247 Participants Needed
Motiva Implants® for Breast Enhancement
Westlake Village, California
This trial studies the safety and effectiveness of Motiva Implants® in women who want to enhance or rebuild their breasts. The implants are surgically inserted to improve breast appearance. The study will track patient outcomes over a long period. Motiva Implants have demonstrated excellent safety and effectiveness in primary breast augmentation over several years.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Sex:Female
Key Eligibility Criteria
Disqualifiers:Breast Disease, Pregnancy, Obesity, Others
Must Not Be Taking:Blood Thinners
800 Participants Needed
Tendyne Transcatheter Mitral Valve System for Mitral Regurgitation
Thousand Oaks, California
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device.
The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) is to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification.
This randomized controlled trial will provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System will be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who are not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and are also not suitable for transcatheter repair with MitraClip, will be enrolled in the Non-repairable cohort.
Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Mitral Vegetation, Ejection Fraction < 25%, Others
958 Participants Needed
Revivent TC System for Heart Failure
Thousand Oaks, California
A prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System, with 2:1 study vs. active concurrent control group allocation ratio. This study will include 126 patients of which 84 patients will be treated with the investigational device and 42 patients will be included in an active control group.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Valvular Disease, Mitral Regurgitation, Coronary Revascularization, Pulmonary Pressure, Others
Must Be Taking:Guideline Directed Medical Therapy
126 Participants Needed
BR-AC for Venous Leg Ulcers
Oxnard, California
This study examines a patient population with a non-healing, non-infected venous leg ulcer (VLU) having adequate arterial perfusion with confirmed venous reflux. It is hypothesized that weekly applications of the human placental allograft BioREtain® Amnion Chorion (BR-AC) applied to a non-healing VLU will result in a higher proportion of wounds showing complete healing within 12 weeks of initiating therapy, compared to standard care alone.
This study has a crossover period, where subjects on standard care alone who do not achieve complete healing within 12 weeks of initiating therapy will be allowed to crossover to receive BR-AC over 12 additional weeks, to evaluate if their wound can achieve complete healing.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Pregnancy, HIV/AIDS, Cancer, Dialysis, Others
Must Not Be Taking:Antibiotics, Cytotoxic Agents, Corticosteroids, TNFα Inhibitors
60 Participants Needed
ShortCut Device for Aortic Valve Stenosis
Thousand Oaks, California
A Prospective, Multicenter, Non-Randomized, Single-Arm, Open-Label Continued Access Study of the ShortCut™ device (The ShortCut™ CAS).
The continued access study will be used to collect additional safety and effectiveness data of the ShortCut™ device for splitting bioprosthetic aortic valve leaflets, and to demonstrate coronary artery ostia patency following leaflet split, in patients who are at risk for TAVR-induced coronary artery ostium obstruction following a ViV procedure.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Carotid Disease, Recent CVA, MI, Others
50 Participants Needed
Left Atrial Appendage Closure Devices for Atrial Fibrillation
Thousand Oaks, California
The purpose of this study is to compare the safety and effectiveness of Laminar Left Atrial Appendage Closure (LAAC) device as compared to the commercially available LAAC devices in participants with non-valvular atrial fibrillation (NVAF) to reduce the risk of stroke (blocked blood vessel or bleeding in brain) and systemic embolism (blockage in a blood vessel harming vital organs).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Stage IV Kidney Disease, Others
Must Be Taking:Oral Anticoagulants
1900 Participants Needed
INSPIRE Stewardship Bundle for Skin and Soft Tissue Infections
Thousand Oaks, California
This trial tests a computer system that helps doctors choose the right antibiotics for adults with skin infections by predicting if the infection will resist common treatments.
No Placebo Group
Trial Details
Trial Status:Completed
Trial Phase:Unphased
Key Eligibility Criteria
Must Be Taking:Extended-spectrum Antibiotics
118562 Participants Needed
PFO Closure Devices for Stroke Prevention
Thousand Oaks, California
The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/procedure related Serious Adverse Events (SAE).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Atrial Fibrillation, Hypertension, Diabetes, Others
Must Not Be Taking:Aspirin, Clopidogrel
450 Participants Needed
Why Other Patients Applied
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
Aortic Valve Replacement for Aortic Stenosis
Thousand Oaks, California
This trial compares two methods of heart valve replacement in patients with severe narrowing of the heart valve. It aims to see if one method is better at improving blood flow and reducing symptoms without needing major surgery.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Multivessel Coronary Disease, Pregnancy, Previous Valve Replacement, Others
1103 Participants Needed
LINQ Sensor Algorithm for Heart Failure
Oxnard, California
This trial tests a small device that monitors heart activity in patients with moderate heart failure. The device uses special software to help doctors manage patient care more effectively.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Not Listed
826 Participants Needed
New Aortic Heart Valves for Aortic Stenosis
Thousand Oaks, California
This trial is testing a new heart valve that can be inserted without open-heart surgery. It targets high-risk patients with severe aortic stenosis. The valve is put in through a small cut and helps the heart pump blood more effectively. This procedure offers an alternative to more invasive surgeries.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Myocardial Infarction, Stroke, Blood Dyscrasias, Others
333 Participants Needed
Know someone looking for new options?
Spread the word